Tag: Ardelyx CKD

FDA, Regulations

FDA panel backs Ardelyx CKD drug, despite agency concerns

November 17, 2022

Via: Pharmaphorum

The Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted yesterday by nine to four that the benefits of Xphozah (tenapanor) outweigh its risks when given as a monotherapy to treat high phosphate levels in the blood in adults with CDK […]